Ren Bolin, Ren Xiaolei, Wang Lu, Tu Chao, Zhang Wenchao, Liu Zhongyue, Qi Lin, Wan Lu, Pang Ke, Tao Cheng, Li Zhihong
Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, China.
Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
Front Pharmacol. 2022 Sep 19;13:929223. doi: 10.3389/fphar.2022.929223. eCollection 2022.
Denosumab is a monoclonal antibody that targets and inhibits the osteoclast activating factor receptor activator for nuclear factor-κB ligand (RANKL). It has been widely used in the treatment of osteoporosis, giant cell tumors of bone, and in the prevention of malignant skeletal-related events (SREs). We collected the research results and related MeSH terms of denosumab from 2011 to 2021 through the Web of Science and PubMed, respectively. The literature was visualized and analyzed by CiteSpace and bibliometric online analysis platforms. The MeSH terms were biclustered using the Bibliographic Co-Occurrence Analysis System (BICOMB) and graph clustering toolkit (gCLUTO). The results show that the number of denosumab-related annual publications had increased from 51 to 215, with the United States leading and Amgen Inc. being the most influential in the past 10 years. Articles published in the Journal of Bone and Mineral Research had the highest total citations. Three scholars from Shinshu University in Matsumoto, Yukio Nakamura, Takako Suzuki, and Hiroyuki Kato, joined the field relatively late but produced the most. The clinical comparison and combination of denosumab with other drugs in the treatment of osteoporosis was the most significant focus of research. Drug withdrawal rebound and management strategies have gained more attention and controversy recently. MeSH analysis revealed eight major categories of research hotspots. Among them, exploring the multiple roles of the RANK-RANKL-OPG system in tumor progression, metastasis, and other diseases is the potential direction of future mechanism research. It is a valuable surgical topic to optimize the perioperative drug administration strategy for internal spinal fixation and orthopedic prosthesis implantation. Taken together, the advantages of denosumab were broad and cost-effective. However, there were still problems such as osteonecrosis of the jaw, severe hypocalcemia, a high recurrence rate of giant cells in the treatment of bone and individual sarcoidosis, and atypical femoral fractures, which need to be adequately solved.
地诺单抗是一种单克隆抗体，它靶向并抑制破骨细胞激活因子核因子κB受体激活配体（RANKL）。它已被广泛用于治疗骨质疏松症、骨巨细胞瘤以及预防恶性骨相关事件（SREs）。我们分别通过科学网和PubMed收集了2011年至2021年地诺单抗的研究成果及相关医学主题词（MeSH）。利用CiteSpace和文献计量在线分析平台对文献进行可视化和分析。使用文献共现分析系统（BICOMB）和图形聚类工具包（gCLUTO）对MeSH词进行双聚类分析。结果表明，在过去10年中，地诺单抗相关年度出版物数量从51篇增加到215篇，美国处于领先地位，安进公司最具影响力。发表在《骨与矿物质研究杂志》上的文章总被引次数最高。来自松本信州大学的三位学者中村幸雄、铃木贵子和加藤博之进入该领域相对较晚，但产出最多。地诺单抗与其他药物治疗骨质疏松症的临床比较及联合应用是最主要的研究重点。停药反弹及管理策略最近受到了更多关注和争议。MeSH分析揭示了八大类研究热点。其中，探索RANK-RANKL-OPG系统在肿瘤进展、转移及其他疾病中的多重作用是未来机制研究的潜在方向。优化脊柱内固定和骨科假体植入围手术期给药策略是一个有价值的外科课题。总体而言，地诺单抗优点广泛且性价比高。然而，仍存在诸如颌骨坏死、严重低钙血症、骨巨细胞瘤治疗中巨细胞高复发率以及个别结节病和非典型股骨骨折等问题，需要妥善解决。
